Gerresheimer（1GXI）株式概要ゲレスハイマーAGは、その子会社とともに、医薬品包装、薬物送達装置、ソリューションをドイツ国内外で製造・販売している。 詳細1GXI ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長3/6過去の実績1/6財務の健全性0/6配当金0/6報酬当社が推定した公正価値より59.9%で取引されている 収益は年間26.75%増加すると予測されています リスク分析Italian市場と比較して、過去 3 か月間の株価の変動が非常に大きい利払いは収益で十分にカバーされない 財務結果に影響を与える大きな一時的項目 利益率(1%)は昨年より低い(5.7%) すべてのリスクチェックを見る1GXI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€26.80該当なし内在価値ディスカウントEst. Revenue$PastFuture-25m3b2016201920222025202620282031Revenue €3.0bEarnings €31.1mAdvancedSet Fair ValueView all narrativesGerresheimer AG 競合他社Fine Foods & Pharmaceuticals N.T.MSymbol: BIT:FFMarket cap: €209.4mChemoMetecSymbol: CPSE:CHEMMMarket cap: DKK 6.4bAkums Drugs and PharmaceuticalsSymbol: NSEI:AKUMSMarket cap: ₹95.6bBeijing Sun-Novo Pharmaceutical ResearchSymbol: SHSE:688621Market cap: CN¥6.0b価格と性能株価の高値、安値、推移の概要Gerresheimer過去の株価現在の株価€26.8052週高値€48.8252週安値€15.80ベータ0.471ヶ月の変化-6.16%3ヶ月変化37.58%1年変化-44.51%3年間の変化n/a5年間の変化n/aIPOからの変化-58.90%最新ニュースValuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €23.80, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Life Sciences industry in Europe. Total loss to shareholders of 56% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €29.72 per share.お知らせ • Apr 11Gerresheimer AG(XTRA:GXI) dropped from Germany SDAX (Total Return) IndexGerresheimer AG has been dropped from the Germany SDAX (Total Return) IndexValuation Update With 7 Day Price Move • Feb 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €21.12, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €30.50 per share.Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €29.80, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Life Sciences industry in Europe.New Risk • Dec 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.0% net profit margin).お知らせ • Nov 22Gerresheimer AG Announces Supervisory Board ChangesKlaus Röhrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresheimer AG until the next Annual General Meeting in June 2026. He succeeds Dr. Dorothea Wenzel, who made her position available to reflect the changed shareholder structure of the company in the composition of the Supervisory Board. With his appointment, Klaus Röhrig also assumes the duties of Dr. Dorothea Wenzel on the Audit Committee of Gerresheimer AG. Klaus Röhrig will stand for election to the Supervisory Board at the next Annual General Meeting on June 3, 2026. In total, four shareholder representatives will be up for election at the next Annual General Meeting of Gerresheimer AG’s co-determined Supervisory Board.最新情報をもっと見るRecent updatesValuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €23.80, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Life Sciences industry in Europe. Total loss to shareholders of 56% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €29.72 per share.お知らせ • Apr 11Gerresheimer AG(XTRA:GXI) dropped from Germany SDAX (Total Return) IndexGerresheimer AG has been dropped from the Germany SDAX (Total Return) IndexValuation Update With 7 Day Price Move • Feb 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €21.12, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €30.50 per share.Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €29.80, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Life Sciences industry in Europe.New Risk • Dec 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.0% net profit margin).お知らせ • Nov 22Gerresheimer AG Announces Supervisory Board ChangesKlaus Röhrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresheimer AG until the next Annual General Meeting in June 2026. He succeeds Dr. Dorothea Wenzel, who made her position available to reflect the changed shareholder structure of the company in the composition of the Supervisory Board. With his appointment, Klaus Röhrig also assumes the duties of Dr. Dorothea Wenzel on the Audit Committee of Gerresheimer AG. Klaus Röhrig will stand for election to the Supervisory Board at the next Annual General Meeting on June 3, 2026. In total, four shareholder representatives will be up for election at the next Annual General Meeting of Gerresheimer AG’s co-determined Supervisory Board.お知らせ • Oct 16+ 3 more updatesGerresheimer AG to Report Fiscal Year 2025 Results on Feb 26, 2026Gerresheimer AG announced that they will report fiscal year 2025 results at 1:25 PM, Central European Standard Time on Feb 26, 2026お知らせ • Oct 14Gerresheimer Ag Announces Fda Grants Approval of Sq Innovation's Lasix®? OnyuGerresheimer announced that the US Food and Drug Administration (FDA) granted SQ Innovation approval for Lasix ONYU for treatment of edema in congestive heart failure. Lasix ONYU is a combination product consisting of a novel high-concentration formulation of the diuretic furosemide and the Gerresheimer on-body drug delivery device (infusor). It was developed to enable subcutaneous infusion of furosemide at home for selected patients, as prescribed by a clinician without the need for a healthcare professional to administer the drug. The cartridge-based infusor was designed and developed by Gerresheimer based on its proprietary infusor platform for subcutaneous drug delivery. Gerresheimer also manages production of the device as a full-service solution provider. First products of Lasix ONYU are expected to be available on the market already in 2025. The FDA's approval of the combination product demonstrates Gerresheimer's innovative strength and its strong partnership with customers, from product design to large-scale manufacturing. Device based on Gerresheimer's innovative micropump technology: The cartridge-based infus or was designed and developed by Ger Resheimer based on its proprietary infUSor platform for subcutaneous Drug delivery. The core technology is an innovative micropump which enables controlled, precise administration of a drug product according to a defined therapy regimen. Designed with patient comfort and the environment in mind The lightweight, compact device is patched onto the patient's body, making it comfortable for the patient to wear while the drug is gently infused. The reusable component, which is rated for delivery of 48 treatments with diuretic furosemides, is recyclable. Because only the disposable unit requires sterilization, radiation can be used instead of chemical sterilization, and no electronic components end up in medical waste. This two-component concept was developed in line with Gerresheimer's EcoDesign principles, which aim to increase product lifespan and reduce waste. Reducing total cost of care and improving patients' quality of life. The combination product Lasix ONYU also opens up possibilities to reduce the total cost of care. The two-component design results in a lower cost per treatment, because only the disposable part of the device needs to be replaced. Most importantly, the infusor allows for home treatment, reducing the length of hospital stay or avoiding the need for hospitalization for intravenous diuretic administration altogether. First products expected to be available already in 2025 In addition to Gerresheimer's role in design and development, Gerresheimer also manages production the device as a full- service solution provider. The disposable unit for the infusor is, for example, produced at the Gerresheimer facility in Wackersdorf, Germany, on a high-capacity semi-automated line. Production commenced earlier this year in anticipation of approval and first products are expected to be available before the end of the year.Reported Earnings • Oct 10Second quarter 2025 earnings released: EPS: €0.49 (vs €0.94 in 2Q 2024)Second quarter 2025 results: EPS: €0.49 (down from €0.94 in 2Q 2024). Revenue: €600.7m (up 20% from 2Q 2024). Net income: €17.0m (down 48% from 2Q 2024). Profit margin: 2.8% (down from 6.5% in 2Q 2024). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €30.30, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 18x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €60.49 per share.お知らせ • Oct 10+ 2 more updatesGerresheimer AG Appoints Hans-Norbert Topp as Head of Combined Moulded Glass Business UnitGerresheimer AG announced that as part of the integration of Bormioli Pharma into the Gerresheimer Group, Gerresheimer has already begun to establish the combined Moulded Glass business as a global, independent unit. Hans-Norbert Topp, an internationally experienced manager with a proven track record, has been appointed to head the business unit.お知らせ • Aug 22Active Ownership Wants Review at Gerresheimer After Taking StakeOn August 21, 2025, Active Ownership announced that it saw major potential for value creation at Gerresheimer AG and called for a strategic review. Active Ownership expressly welcomes the planned sale process for the moulded glass division and calls for a swift settlement in order to strengthen the Company's cash flow and reduce debt. Active Ownership also stated that further key measures should include additional portfolio optimization and the implementation of an efficiency programme, particularly through cost reductions in administration and business units. Active Ownership added that this would improve the return on the Company's sales by five percentage points, while also calling for the creation of a strategy committee to review all of the Company's ongoing projects.お知らせ • Jul 11Gerresheimer AG Provides Revenue Guidance for the Second Half of 2025Gerresheimer AG provided revenue guidance for the second half of 2025. In the second half of 2025, Gerresheimer expects stronger growth again based on production ramp-ups and a good order intake, and anticipates organic revenue growth of 0 – 2% compared to the previous year.お知らせ • Jun 06Asset Value Investors Calls for Changes at Gerresheimer AGOn June 5, 2025, Asset Value Investors Limited called upon Gerresheimer AG to take steps to restore its market value, a move partially supported by another top 30 investor. Asset Value Investors expressed its views that new financial leadership is needed to restore the Company's relationship and credibility with investors, it said in an open letter to the Company. Asset Value Investors also urged the Company to establish a capital allocation committee and exit its moulded glass business as soon as possible. Union Investment, which holds a 0.9% stake in the Company, said it backed the calls for new leadership and a sale of the moulded glass business but did not see a need for a capital allocation committee.お知らせ • Jun 05+ 1 more updateGerresheimer AG Revises Earnings Guidance for the Financial Year 2025Gerresheimer AG revised earnings guidance for the financial year 2025. For the financial year, the company expects organic revenue growth to be 1% to 2% compared to the previous year (previously: 3% to 5%).お知らせ • Apr 24Gerresheimer AG, Annual General Meeting, Jun 05, 2025Gerresheimer AG, Annual General Meeting, Jun 05, 2025, at 10:00 W. Europe Standard Time.お知らせ • Apr 11Gerresheimer AG Confirms Earnings Guidance for the Mid-Term of the Fiscal Year 2025Gerresheimer AG confirmed earnings guidance for the mid-term of the fiscal year 2025. For the mid-term, the company expects organic revenue growth 8% - 10% CAGR.お知らせ • Mar 13Warburg Pincus, KKR Consortium Reportedly in Talks to Buy GerresheimerA consortium consisting of Warburg Pincus LLC and KKR & Co. Inc. (NYSE:KKR) are in talks to acquire Gerresheimer AG (ETR:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The private equity firms emerged as the frontrunner after they teamed up and other potential bidders including Bain Capital dropped, the people said, asking not to be identified discussing confidential information. The Warburg Pincus-KKR consortium is unlikely to offer a significant premium to Gerresheimer’s current price and there are still major hurdles to a deal, some of the people said. While the talks are advanced, any final agreement could take weeks and a deal could still fall apart, they added. Representatives for Gerresheimer, Warburg Pincus, KKR and Bain declined to comment.お知らせ • Feb 27Gerresheimer AG announces Annual dividend, payable on June 10, 2025Gerresheimer AG announced Annual dividend of EUR 1.2500 per share payable on June 10, 2025, ex-date on June 06, 2025 and record date on June 09, 2025.株主還元1GXIIT Life SciencesIT 市場7D7.2%6.9%-2.7%1Y-44.5%-6.3%23.3%株主還元を見る業界別リターン: 1GXI過去 1 年間で-6.3 % の収益を上げたItalian Life Sciences業界を下回りました。リターン対市場: 1GXIは、過去 1 年間で23.3 % のリターンを上げたItalian市場を下回りました。価格変動Is 1GXI's price volatile compared to industry and market?1GXI volatility1GXI Average Weekly Movement8.9%Life Sciences Industry Average Movement6.5%Market Average Movement4.8%10% most volatile stocks in IT Market8.6%10% least volatile stocks in IT Market3.0%安定した株価: 1GXIの株価は、 Italian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 1GXIの weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてItalianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト186413,535Uwe Röehrhoffwww.gerresheimer.comゲレスハイマーAGは、その子会社とともに、医薬品包装、ドラッグデリバリーデバイス、ソリューションをドイツ国内外で製造・販売している。同社は3つの部門を通じて事業を展開している：プラスチック＆デバイス、一次包装用ガラス、先端技術の3部門。同社は、プレフィラブルシリンジ、プラスチックおよびガラス製パッケージングソリューション、バイアル、ガラス製カートリッジおよびアンプル、ボトルおよび容器、ガラス製ボトルおよびジャー、ならびにキャップ、クロージャー、アプリケーターおよびアクセサリー、薬物送達プログラムの開発、工業化および受託製造、プロジェクトおよび品質管理、ならびに吸入器、注射器／自動注射器、ペン型注射器、注入システム、吸入評価などの薬物送達システム、自動注射器、およびその他のサービスを提供している。また、ポイントオブケアテスト、ラボ用ディスポーザブル、薬品・技術用ボトル、診断用ポリマーバイアル、スポイトボトル、PETボトルなどの診断・医療機器や、ランシングデバイス、輸液セット、ディスポーザブルシステムなどの医療製品も提供している。さらに、成型ガラス製フラスコやジャー、管状ガラス製アンプル、スポイト、サンプラー、バイアル、プラスチック製パッケージング製品などの化粧品パッケージング・ソリューションや、医薬品、ラボラトリー、薬事サービスを提供している。薬局チェーン、スーパーマーケット、卸売業者に製品を提供している。同社は製薬、バイオテクノロジー、医療技術、診断、化粧品、ガラス容器、食品・飲料業界にサービスを提供している。ゲレスハイマー社は1864年に設立され、ドイツのデュッセルドルフに本社を置いている。もっと見るGerresheimer AG 基礎のまとめGerresheimer の収益と売上を時価総額と比較するとどうか。1GXI 基礎統計学時価総額€949.85m収益（TTM）€23.35m売上高(TTM)€2.25b40.7xPER（株価収益率0.4xP/Sレシオ1GXI は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1GXI 損益計算書（TTM）収益€0売上原価€0売上総利益€0その他の費用€0収益€0直近の収益報告Nov 30, 2025次回決算日Jul 14, 2026一株当たり利益（EPS）0.68グロス・マージン26.89%純利益率1.04%有利子負債／自己資本比率155.5%1GXI の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.1%現在の配当利回り6%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/29 00:19終値2026/06/29 00:00収益2025/11/30年間収益2025/11/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Gerresheimer AG 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。34 アナリスト機関Jonathon UnwinBarclaysPallav MittalBarclaysGaurav JainBarclays31 その他のアナリストを表示
Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €23.80, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Life Sciences industry in Europe. Total loss to shareholders of 56% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €29.72 per share.
お知らせ • Apr 11Gerresheimer AG(XTRA:GXI) dropped from Germany SDAX (Total Return) IndexGerresheimer AG has been dropped from the Germany SDAX (Total Return) Index
Valuation Update With 7 Day Price Move • Feb 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €21.12, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €30.50 per share.
Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €29.80, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Life Sciences industry in Europe.
New Risk • Dec 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.0% net profit margin).
お知らせ • Nov 22Gerresheimer AG Announces Supervisory Board ChangesKlaus Röhrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresheimer AG until the next Annual General Meeting in June 2026. He succeeds Dr. Dorothea Wenzel, who made her position available to reflect the changed shareholder structure of the company in the composition of the Supervisory Board. With his appointment, Klaus Röhrig also assumes the duties of Dr. Dorothea Wenzel on the Audit Committee of Gerresheimer AG. Klaus Röhrig will stand for election to the Supervisory Board at the next Annual General Meeting on June 3, 2026. In total, four shareholder representatives will be up for election at the next Annual General Meeting of Gerresheimer AG’s co-determined Supervisory Board.
Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €23.80, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Life Sciences industry in Europe. Total loss to shareholders of 56% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €29.72 per share.
お知らせ • Apr 11Gerresheimer AG(XTRA:GXI) dropped from Germany SDAX (Total Return) IndexGerresheimer AG has been dropped from the Germany SDAX (Total Return) Index
Valuation Update With 7 Day Price Move • Feb 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €21.12, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €30.50 per share.
Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €29.80, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Life Sciences industry in Europe.
New Risk • Dec 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.0% net profit margin).
お知らせ • Nov 22Gerresheimer AG Announces Supervisory Board ChangesKlaus Röhrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresheimer AG until the next Annual General Meeting in June 2026. He succeeds Dr. Dorothea Wenzel, who made her position available to reflect the changed shareholder structure of the company in the composition of the Supervisory Board. With his appointment, Klaus Röhrig also assumes the duties of Dr. Dorothea Wenzel on the Audit Committee of Gerresheimer AG. Klaus Röhrig will stand for election to the Supervisory Board at the next Annual General Meeting on June 3, 2026. In total, four shareholder representatives will be up for election at the next Annual General Meeting of Gerresheimer AG’s co-determined Supervisory Board.
お知らせ • Oct 16+ 3 more updatesGerresheimer AG to Report Fiscal Year 2025 Results on Feb 26, 2026Gerresheimer AG announced that they will report fiscal year 2025 results at 1:25 PM, Central European Standard Time on Feb 26, 2026
お知らせ • Oct 14Gerresheimer Ag Announces Fda Grants Approval of Sq Innovation's Lasix®? OnyuGerresheimer announced that the US Food and Drug Administration (FDA) granted SQ Innovation approval for Lasix ONYU for treatment of edema in congestive heart failure. Lasix ONYU is a combination product consisting of a novel high-concentration formulation of the diuretic furosemide and the Gerresheimer on-body drug delivery device (infusor). It was developed to enable subcutaneous infusion of furosemide at home for selected patients, as prescribed by a clinician without the need for a healthcare professional to administer the drug. The cartridge-based infusor was designed and developed by Gerresheimer based on its proprietary infusor platform for subcutaneous drug delivery. Gerresheimer also manages production of the device as a full-service solution provider. First products of Lasix ONYU are expected to be available on the market already in 2025. The FDA's approval of the combination product demonstrates Gerresheimer's innovative strength and its strong partnership with customers, from product design to large-scale manufacturing. Device based on Gerresheimer's innovative micropump technology: The cartridge-based infus or was designed and developed by Ger Resheimer based on its proprietary infUSor platform for subcutaneous Drug delivery. The core technology is an innovative micropump which enables controlled, precise administration of a drug product according to a defined therapy regimen. Designed with patient comfort and the environment in mind The lightweight, compact device is patched onto the patient's body, making it comfortable for the patient to wear while the drug is gently infused. The reusable component, which is rated for delivery of 48 treatments with diuretic furosemides, is recyclable. Because only the disposable unit requires sterilization, radiation can be used instead of chemical sterilization, and no electronic components end up in medical waste. This two-component concept was developed in line with Gerresheimer's EcoDesign principles, which aim to increase product lifespan and reduce waste. Reducing total cost of care and improving patients' quality of life. The combination product Lasix ONYU also opens up possibilities to reduce the total cost of care. The two-component design results in a lower cost per treatment, because only the disposable part of the device needs to be replaced. Most importantly, the infusor allows for home treatment, reducing the length of hospital stay or avoiding the need for hospitalization for intravenous diuretic administration altogether. First products expected to be available already in 2025 In addition to Gerresheimer's role in design and development, Gerresheimer also manages production the device as a full- service solution provider. The disposable unit for the infusor is, for example, produced at the Gerresheimer facility in Wackersdorf, Germany, on a high-capacity semi-automated line. Production commenced earlier this year in anticipation of approval and first products are expected to be available before the end of the year.
Reported Earnings • Oct 10Second quarter 2025 earnings released: EPS: €0.49 (vs €0.94 in 2Q 2024)Second quarter 2025 results: EPS: €0.49 (down from €0.94 in 2Q 2024). Revenue: €600.7m (up 20% from 2Q 2024). Net income: €17.0m (down 48% from 2Q 2024). Profit margin: 2.8% (down from 6.5% in 2Q 2024). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €30.30, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 18x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €60.49 per share.
お知らせ • Oct 10+ 2 more updatesGerresheimer AG Appoints Hans-Norbert Topp as Head of Combined Moulded Glass Business UnitGerresheimer AG announced that as part of the integration of Bormioli Pharma into the Gerresheimer Group, Gerresheimer has already begun to establish the combined Moulded Glass business as a global, independent unit. Hans-Norbert Topp, an internationally experienced manager with a proven track record, has been appointed to head the business unit.
お知らせ • Aug 22Active Ownership Wants Review at Gerresheimer After Taking StakeOn August 21, 2025, Active Ownership announced that it saw major potential for value creation at Gerresheimer AG and called for a strategic review. Active Ownership expressly welcomes the planned sale process for the moulded glass division and calls for a swift settlement in order to strengthen the Company's cash flow and reduce debt. Active Ownership also stated that further key measures should include additional portfolio optimization and the implementation of an efficiency programme, particularly through cost reductions in administration and business units. Active Ownership added that this would improve the return on the Company's sales by five percentage points, while also calling for the creation of a strategy committee to review all of the Company's ongoing projects.
お知らせ • Jul 11Gerresheimer AG Provides Revenue Guidance for the Second Half of 2025Gerresheimer AG provided revenue guidance for the second half of 2025. In the second half of 2025, Gerresheimer expects stronger growth again based on production ramp-ups and a good order intake, and anticipates organic revenue growth of 0 – 2% compared to the previous year.
お知らせ • Jun 06Asset Value Investors Calls for Changes at Gerresheimer AGOn June 5, 2025, Asset Value Investors Limited called upon Gerresheimer AG to take steps to restore its market value, a move partially supported by another top 30 investor. Asset Value Investors expressed its views that new financial leadership is needed to restore the Company's relationship and credibility with investors, it said in an open letter to the Company. Asset Value Investors also urged the Company to establish a capital allocation committee and exit its moulded glass business as soon as possible. Union Investment, which holds a 0.9% stake in the Company, said it backed the calls for new leadership and a sale of the moulded glass business but did not see a need for a capital allocation committee.
お知らせ • Jun 05+ 1 more updateGerresheimer AG Revises Earnings Guidance for the Financial Year 2025Gerresheimer AG revised earnings guidance for the financial year 2025. For the financial year, the company expects organic revenue growth to be 1% to 2% compared to the previous year (previously: 3% to 5%).
お知らせ • Apr 24Gerresheimer AG, Annual General Meeting, Jun 05, 2025Gerresheimer AG, Annual General Meeting, Jun 05, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Apr 11Gerresheimer AG Confirms Earnings Guidance for the Mid-Term of the Fiscal Year 2025Gerresheimer AG confirmed earnings guidance for the mid-term of the fiscal year 2025. For the mid-term, the company expects organic revenue growth 8% - 10% CAGR.
お知らせ • Mar 13Warburg Pincus, KKR Consortium Reportedly in Talks to Buy GerresheimerA consortium consisting of Warburg Pincus LLC and KKR & Co. Inc. (NYSE:KKR) are in talks to acquire Gerresheimer AG (ETR:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The private equity firms emerged as the frontrunner after they teamed up and other potential bidders including Bain Capital dropped, the people said, asking not to be identified discussing confidential information. The Warburg Pincus-KKR consortium is unlikely to offer a significant premium to Gerresheimer’s current price and there are still major hurdles to a deal, some of the people said. While the talks are advanced, any final agreement could take weeks and a deal could still fall apart, they added. Representatives for Gerresheimer, Warburg Pincus, KKR and Bain declined to comment.
お知らせ • Feb 27Gerresheimer AG announces Annual dividend, payable on June 10, 2025Gerresheimer AG announced Annual dividend of EUR 1.2500 per share payable on June 10, 2025, ex-date on June 06, 2025 and record date on June 09, 2025.
